Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

Completed · Phase 2

Conditions studied: Metastatic Colorectal Cancer

In brief

The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications.

Key facts

Study ID

NCT00205322

Run by

University of Wisconsin, Madison

People needed

45

Starts

2004-04-01

Expected to finish

2007-10-01

Last updated by the study team

2019-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• no prior treatment for metastatic disease
• PS 0-2
• measurable disease

You may not qualify if…

• neuropathy > or equal to grade 2
• concomitant radiation therapy or other systemic cancer therapies
• brain mets

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.